Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY)

Q: What does CUSIP 90466Y202 represent in this 13F holders report?

CUSIP 90466Y202 is the security identifier for UNCY - Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share used to aggregate holder disclosures.

Q: How many institutions held UNCY - Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share in Q4 2025?

34 institutional investors reported UNCY - Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 90466Y202

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock, $0.001 par value per share
Shares outstanding: 28,293,758
Total 13F shares: 8,144,623
Share change: +1,782,956
Total reported value: $47,021,122
Price per share: $5.77
Number of holders: 34
Value change: +$10,346,527
Number of buys: 14
Number of sells: 8

Quarterly Holders Quick Answers

What is CUSIP 90466Y202?
CUSIP 90466Y202 identifies UNCY - Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 90466Y202:

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Top shareholders of UNCY - Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Vivo Opportunity Fund Holdings, L.P.	13D/G	—	10%	6,096,175	$26,579,323	$0	30 Sep 2025	13D/G
Nantahala Capital Management, LLC	13D/G 13F	Company	10%	2,281,040	$13,389,705	$0	31 Dec 2025	13D/G 13F
Gaurav Aggarwal	3/4/5	Director	— mixed-class rows	1,829,115 mixed-class rows	$8,430,499	—	25 Aug 2025	3/4/5
RA CAPITAL MANAGEMENT, L.P.	13D/G	—	9.9%	13,285,781	$8,370,042	+$1,112,366	31 Mar 2025	13D/G
Vivo Capital, LLC	13F	Company	6.3%	1,789,916	$7,804,034	—	30 Sep 2025	13F
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	10%	1,417,117	$7,439,864	$0	30 Jun 2025	13D/G
Octagon Capital Advisors LP	13D/G 13F	Company	4.7%	1,000,000	$5,870,000	$0	31 Dec 2025	13D/G 13F
GREAT POINT PARTNERS LLC	13F 13D/G	Company	4.5% from 13D/G	796,558	$3,472,993	—	30 Sep 2025	13F 13D/G
Walleye Capital LLC	13D/G	—	4.8%	5,000,000	$3,150,000	$0	31 Dec 2024	13D/G
VANGUARD GROUP INC	13F	Company	2.3%	658,878	$2,872,708	—	30 Sep 2025	13F
Logos Global Management LP	13F	Company	1.7%	473,563	$2,064,735	—	30 Sep 2025	13F
Nantahala Capital Partners Limited Partnership	13D/G	—	2.8%	3,009,021	$1,895,683	-$3,073,653	19 Dec 2024	13D/G
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.44%	125,727	$548,168	—	30 Sep 2025	13F
Squarepoint Ops LLC	13F	Company	0.41%	117,327	$511,546	—	30 Sep 2025	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.21%	59,985	$261,535	—	30 Sep 2025	13F
STATE STREET CORP	13F	Company	0.19%	54,827	$239,046	—	30 Sep 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.16%	45,200	$197,072	—	30 Sep 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.15%	41,674	$181,699	—	30 Sep 2025	13F
XTX Topco Ltd	13F	Company	0.13%	37,823	$164,908	—	30 Sep 2025	13F
BlackRock, Inc.	13F	Company	0.13%	36,355	$158,508	—	30 Sep 2025	13F
NORTHERN TRUST CORP	13F	Company	0.12%	32,699	$142,568	—	30 Sep 2025	13F
Chicago Partners Investment Group LLC	13F	Company	0.1%	26,961	$127,256	—	30 Sep 2025	13F
Cubist Systematic Strategies, LLC	13F	Company	0.08%	23,947	$104,409	—	30 Sep 2025	13F
MORGAN STANLEY	13F	Company	0.04%	10,612	$46,268	—	30 Sep 2025	13F
CITIGROUP INC	13F	Company	0.02%	6,692	$29,177	—	30 Sep 2025	13F
UBS Group AG	13F	Company	0.02%	5,445	$23,740	—	30 Sep 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	827	$3,606	—	30 Sep 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	560	$2,442	—	30 Sep 2025	13F
Rockefeller Capital Management L.P.	13F	Company	0%	500	$2,180	—	30 Sep 2025	13F
TFC Financial Management, Inc.	13F	Company	0%	300	$1,308	—	30 Sep 2025	13F
Fortitude Family Office, LLC	13F	Company	0%	107	$467	—	30 Sep 2025	13F
HARBOUR INVESTMENTS, INC.	13F	Company	0%	100	$436	—	30 Sep 2025	13F
BARCLAYS PLC	13F	Company	0%	80	$349	—	30 Sep 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	55	$240	—	30 Sep 2025	13F
Bogart Wealth, LLC	13F	Company	0%	6	$26	—	30 Sep 2025	13F
DANSKE BANK A/S	13F	Company	0%	1	$4	—	30 Sep 2025	13F
Shalabh K. Gupta	3/4/5	CEO, Director	— class O/S missing	968,951	—	—	28 Jul 2025	3/4/5
Pramod Gupta	3/4/5	EVP, Pharmaceuticals and BD	— class O/S missing	301,986	—	—	28 Jul 2025	3/4/5
Douglas Jermasek	3/4/5	EVP of Corporate Strategy	— class O/S missing	215,500	—	—	28 Jul 2025	3/4/5
John L. Ryan	3/4/5	Director	— class O/S missing	123,775	—	—	05 Sep 2023	3/4/5
John Townsend	3/4/5	Chief Financial Officer	— class O/S missing	101,557	—	—	28 Jul 2025	3/4/5
Brigitte Schiller	3/4/5	Director	— class O/S missing	41,738	—	—	15 Jul 2022	3/4/5
Sandeep Laumas	3/4/5	Director	— class O/S missing	41,286	—	—	28 Jul 2025	3/4/5
Sara Kenkare-Mitra	3/4/5	Director	— class O/S missing	39,200	—	—	28 Jul 2025	3/4/5

Institutional Holders of Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY) as of Q4 2025

As of 31 Dec 2025, Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY) was held by 34 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 8,144,623 shares. The largest 10 holders included Vivo Capital, LLC, MILLENNIUM MANAGEMENT LLC, Octagon Capital Advisors LP, Nantahala Capital Management, LLC, GREAT POINT PARTNERS LLC, VANGUARD GROUP INC, Logos Global Management LP, CITADEL ADVISORS LLC, CANTOR FITZGERALD, L. P., and GEODE CAPITAL MANAGEMENT, LLC. This page lists 34 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.